Loading clinical trials...
Loading clinical trials...
A Phase 1 Relative Bioavailability and Food Effect Study of ABBV-668 Extended-Release Formulations
Conditions
Interventions
ABBV-668 IR
ABBV-668 ER
Locations
1
United States
Acpru /Id# 266960
Grayslake, Illinois, United States
Start Date
July 9, 2024
Primary Completion Date
September 20, 2024
Completion Date
September 20, 2024
Last Updated
October 8, 2024
NCT07310264
NCT06342713
NCT07472361
NCT06823947
NCT06649110
NCT07240675
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions